| Emily Martin, FNP | |
|
584 Roosevelt Trl, Windham, ME 04062-7302 | |
| (207) 892-3233 | |
| Not Available |
| Full Name | Emily Martin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 584 Roosevelt Trl, Windham, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609246834 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP2300X | Nurse Practitioner - Primary Care | CNP151081 (Maine) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | CNP151081 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
| Maine Medical Partners | 9335043967 | 789 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467477349 PECOS PAC ID: 9335043967 Enrollment ID: O20031125000026 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144245028 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000321 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Martin, FNP 584 Roosevelt Trl, Windham, ME 04062-7302 Ph: (207) 892-3233 | Emily Martin, FNP 584 Roosevelt Trl, Windham, ME 04062-7302 Ph: (207) 892-3233 |
News Archive
The ability to find the Lyme spirochete-the tick-borne agent responsible-in the blood is itself an achievement because existing methods of culturing blood were not sensitive enough to detect its presence until College researchers developed a new technique, which they used in the study.
Cornell University researchers have developed a reliable method to distinguish memory declines associated with healthy aging from the more-serious memory disorders years before obvious symptoms emerge. The method also allows research to accurately predict who is more likely to develop cognitive impairment without expensive tests or invasive procedures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.
› Verified 4 days ago
Volha A Grant, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 582 Roosevelt Trl, Windham, ME 04062 Phone: 207-892-3233 Fax: 207-893-0752 | |
Hope Leblanc, N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 17 Mallison Falls Rd, Windham, ME 04062 Phone: 207-893-7080 Fax: 207-892-0173 | |
Jessica Fossett, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 17 Mallison Falls Rd, Windham, ME 04062 Phone: 207-893-7000 | |
Kelly Christine Guildford, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 409 Roosevelt Trl, Windham, ME 04062 Phone: 207-400-8600 | |
Ashly Jewell, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 582 Roosevelt Trl, Windham, ME 04062 Phone: 207-892-3233 | |
Sarah Hiebert, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 110 Tandberg Trl, Windham, ME 04062 Phone: 207-893-8359 |